Xiconic’s Lead Proprietary Product: XCN-010

Third Science.png

First-in-class antibody target: Activated matriptase (actM)

  • A highly cancer-specific antigen overexpressed on multiple epithelial tumors and certain lymphomas(1)

  • Participates with multiple drivers of tumor invasiveness and metastases(2)

Proprietary PEGylation technology(3) improves linker characteristics

  • Reduces potential for off-target toxicities(4)

    • Decreases hydrophobicity and aggregation

  • Facilitates efficient intracellular drug release

  • Preserves core moiety used in FDA-approved ADCs

  • Stable in circulation; intracellular cleavage by cathepsin B

Broadly cytotoxic payload and DAR

  • Monomethyl auristatin E (MMAE), a potent microtubule inhibitor used in three FDA-approved ADCs(5)

  • Drug antibody ratio of 3.5 MMAE/mAb accepted by FDA

(1) Bertino, Oncotarget 2018; (2) Lee J Cancer Molecules 2006; (3) U.S. Patent application US2019/0151464A1; (4) Simmons, Tox App Pharma 2020; (5) ADCERTRIS, POLIVY, PADCEV.

XCN-010 is Highly Active in vitro

Fourth Science.png

*Positive (target) or negative (control) for actM

XCN-010 Preclinical Data Conclusions:

Highly-potent 50% inhibitory concentrations (IC50) only on actM+ tumor cells in vitro

  • Low µg/mL IC50 activity against breast, non-small cell lung and prostate tumors and mantle cell lymphoma

  • Delivers picomolar IC50 equivalents of MMAE

  • Active against a range of other actM+ epithelial tumors

    • Gastric, ovarian and pancreatic

In vivo efficacy observed in several tumor models

  • Two triple negative breast cancer xenograft tumor models MDA-MB-231 and MDA-MB-468

  • Combination with olaparib in MDA-MB-468 xenograft model shows enhanced antitumor efficacy without toxicity

  • Non-small cell lung cancer (H322) and castration-resistant prostate cancer (DU145)

  • Mantle cell lymphoma (JeKo1)

Broad potential indications for XCN-010 support advancement to clinical studies